Real‐world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety

Secukinumab demonstrated high efficacy and favorable safety profile in patients with moderate‐to‐severe plaque psoriasis (PsO) in clinical trials. However, understanding of patient characteristics and clinical outcomes in real world in Thailand is still limited. To describe patient characteristics, effectiveness and safety of secukinumab in Thai PsO patients. This retrospective study analyzed data from medical records of adult PsO patients who initiated secukinumab at 7 dermatology centers from September 2017 to April 2021. Study outcomes included patient characteristics and changes in Psoriasis Area and Severity Index (PASI) score from baseline at weeks 4 and 16 after secukinumab initiation. Adverse events were recorded. Subgroup analyses by adherence rate and completeness of loading dose were performed. Of 163 patients, the mean (SD) age was 44.0 (14.0) years. Most patients (84.7%) were previously treated with topical therapy while 62.0% and 21.5% of patients had received systemic and biologic therapy, respectively. The mean baseline PASI score was 15.4 (9.3). Overall, the mean PASI score improved by 58.0% at week 4 and 78.4% at week 16. Statistically significant differences in PASI approvement were revealed among subgroups of patients with different loading dose and adherence rate. Adverse effects were reported in 8.0% of patients. The characteristics of patients in this study were slightly different from clinical trials in terms of demographic and clinical characteristics, as well as PsO treatment. Secukinumab was effective and safe in Thai patients with PsO, especially among those with complete loading dose and a higher adherence rate.

[1]  P. Foley,et al.  Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study , 2022, Dermatology and Therapy.

[2]  P. Rattanakaemakorn,et al.  Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events. , 2021, Asian Pacific journal of allergy and immunology.

[3]  Xue Shen,et al.  Cognitive Process of Psoriasis and Its Comorbidities: From Epidemiology to Genetics , 2021, Frontiers in Genetics.

[4]  A. Armstrong,et al.  Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records , 2021, Dermatology and Therapy.

[5]  Jian-Zhong Zhang,et al.  Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study , 2021, Chinese medical journal.

[6]  M. Ohtsuki,et al.  Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan , 2020, The Journal of dermatology.

[7]  A. Armstrong,et al.  Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. , 2020, JAMA.

[8]  C. Peralta,et al.  Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  J. Martínez-Ortega,et al.  Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. , 2019, Journal of psychosomatic research.

[10]  M. Rovaris,et al.  Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis , 2019, The British journal of dermatology.

[11]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. , 2019, Journal of the American Academy of Dermatology.

[12]  A. Salman,et al.  Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study* , 2018, Anais brasileiros de dermatologia.

[13]  K. Peris,et al.  Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation , 2018, Expert Opinion on Biological Therapy.

[14]  C. Papavassilis,et al.  Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies , 2018, Drugs & Aging.

[15]  L. Iversen,et al.  Old and New Biological Therapies for Psoriasis , 2017, International journal of molecular sciences.

[16]  S. John,et al.  A systematic review of worldwide epidemiology of psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  R. Althin,et al.  Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients , 2017, BioDrugs.

[18]  S. Tee,et al.  A prospective cross‐sectional study of anxiety and depression in patients with psoriasis in Singapore , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  R. Althin,et al.  Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice , 2016, BioDrugs.

[20]  B. Yoo,et al.  Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis , 2016, The Annals of pharmacotherapy.

[21]  F. Capon,et al.  Update on psoriasis immunopathogenesis and targeted immunotherapy , 2015, Seminars in Immunopathology.

[22]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.

[23]  K. McKeage,et al.  Secukinumab: First Global Approval , 2015, Drugs.

[24]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[25]  B. Kirkham,et al.  Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis , 2014, Immunology.

[26]  S. Jiamton,et al.  The factors affecting quality of life in Thai psoriasis patients. , 2013, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[27]  D. Furst The risk of infections with biologic therapies for rheumatoid arthritis. , 2010, Seminars in arthritis and rheumatism.

[28]  K. Reich,et al.  Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany , 2008, Dermatology.

[29]  R. Stern,et al.  Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. , 2006, The Journal of investigative dermatology.

[30]  Prevalence and Characteristics of Psoriasis Patients in a Primary Care Area in Thailand , 2022, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.